Pluristem accelerates its Cell Therapy program thanks to the EMA

24/05/2015 - 2 minutes

Pluristem Therapeutics has good reasons to celebrate: its PLX cell program in critical limb ischemia is taking the fast line to the market. The program is the first to have been selected for the European Medicines Agency’s Adaptive Pathways pilot project, which aims at accelerating the access for patients to new medicines.

The purpose of Europe’s Adaptive Pathways is to shorten the time it takes for innovative medicines to reach patients with serious conditions that lack adequate treatment options. After a therapy is selected for the program, the Adaptive Pathway’s group begins intensive discussions and provides guidance to the applicant regarding the formal regulatory processes that precede a trial targeting early approval and further expansion of the indications.

However, the Adaptive Pathway doesn’t guarantee the success of the PLX cell program. Nevertheless the possibility of an early approval represents a tremendous milestone for Pluristem, as Zami Aberman, the company’s CEO stated.

The company relies on its proprietary PLX cell program to achieve its long-term strategy to lead the cell therapy industry.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member